Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesity-related glomerulopathy

American Journal of the Medical Sciences

Volumn 346, Issue 4, 2013, Pages 295-301

  Wang, Xufang ^a   Chen, Huimei ^a   Zhang, Mingchao ^a   Liu, Zhihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Glomerulopathy; Mast cell; Monocyte chemoattractant protein 1; Obesity

Indexed keywords

CD68 ANTIGEN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TRYPTASE;

ADULT; ARTICLE; ATROPHY; BODY MASS; CELL COUNT; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ENZYME LOCALIZATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; KIDNEY TUBULE DISORDER; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MAST CELL; OBESITY; OBESITY RELATED GLOMERULOPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTOLIC BLOOD PRESSURE;

EID: 84885022721     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31827559f8     Document Type: Article

References (37)

1. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-405 (Pubitemid 40523734)
2. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509 (Pubitemid 32281241)
3. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 2006;15:481-6
4. Wu Y, Liu Z, Xiang Z, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006;147:44-50 (Pubitemid 43004261)
5. Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004;65:116-28 (Pubitemid 38037496)
6. Giunti S, Barutta F, Perin PC, et al. Targeting the MCP-1/CCR2 System in diabetic kidney disease. Curr Vasc Pharmacol 2010;8: 849-60
7. Theoharides TC, Sismanopoulos N, Delivanis DA, et al. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci 2011;32:534-42
8. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009;15:940-45
9. Hiromura K, Kurosawa M, Yano S, et al. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis 1998;32:593-99 (Pubitemid 28477705)
10. Solari V, Unemoto K, Piaseczna Piotrowska A, et al. Increased expression of mast cells in reflux nephropathy. Pediatr Nephrol 2004; 19:157-63 (Pubitemid 38181007)
11. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol 2008;19:2254-61
12. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004;66: 920-3
13. Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002;15:83-96
14. Praga M, Hernandez E, Morales E, et al. Clinical features and longterm outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-8 (Pubitemid 32821410)
15. Chen HM, Li SJ, Chen HP, et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008;52:58-65
16. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:117-34 (Pubitemid 36397094)
17. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 1986;261:7372-9 (Pubitemid 17224739)
18. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int 1998;54:1675-83 (Pubitemid 28502910)
19. Grutzkau A, Kruger-Krasagakes S, Kogel H, et al. Detection of intracellular interleukin-8 in human mast cells: flow cytometry as a guide for immunoelectron microscopy. J Histochem Cytochem 1997;45: 935-45 (Pubitemid 27284017)
20. Jones SE, Kelly DJ, Cox AJ, et al. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 2003;64:906-13 (Pubitemid 37013826)
21. Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011;412:1171-9
22. Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett 2010;128:36-45
23. Kondo S, Kagami S, Kido H, et al. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001;12:1668-76 (Pubitemid 32674429)
24. Mack M, Rosenkranz AR. Basophils and mast cells in renal injury. Kidney Int 2009;76:1142-7
25. Feuser K, Thon KP, Bischoff SC, et al. Human intestinal mast cells are a potent source of multiple chemokines. Cytokine 2012;58:178-85
26. Chow FY, Nikolic-Paterson DJ, Ma FY, et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007;50:471-80
27. Ingersoll MA, Platt AM, Potteaux S, et al. Monocyte trafficking in acute and chronic inflammation. Trends Immunol 2011;32:470-7
28. Shen WW, Chen HM, Chen H, et al. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010;5: 1401-9
29. El-Koraie AF, Baddour NM, Adam AG, et al. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 2001;60:167-72 (Pubitemid 32587551)
30. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A 2004;101:13607-12 (Pubitemid 39238450)
31. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1063-70
32. Huang XR, Chen WY, Truong LD, et al. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47 (Pubitemid 36750469)
33. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003;107:2555-8 (Pubitemid 36628935)
34. Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011;128:147-152.e142
35. Molderings GJ, Meis K, Kolck UW, et al. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010;62:721-7
36. Miyazawa S, Hotta O, Doi N, et al. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int 2004; 65:2228-37 (Pubitemid 38670009)
37. Jung YJ, et al. Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 2009;75:1031-8.